CSF2 and neuroblastoma: A randomized clinical trial demonstrated a significant improvement of patient outcomes (improved event-free survival and overall survival) when Dinutuximab was used in combination with a granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin-2, and 13-cis retinoic acid in the treatment of pediatric patients with high-risk neuroblastoma after a first multiagent/multimodal therapy [100].